Novo Nordisk raises sales and operating profit outlook for 2021
October 29 2021 - 9:04AM
Novo Nordisk raises sales and operating profit outlook for 2021
Bagsværd, Denmark, 29
October 2021
– Novo Nordisk today announced that the full-year
sales and operating profit outlook at constant exchange rates (CER)
has been raised.
In the third quarter of 2021, Novo Nordisk’s sales increased by
15% and operating profit increased by 19%, both at CER. The
operating profit increase was positively impacted by the
amortisation of the priority review voucher for Wegovy™ in the
third quarter of 2020.
Profit and loss (CER) |
First nine months
2021 |
Third quarter
2021 |
Net sales growth |
13% |
15% |
Operating profit growth |
12% |
19% |
Following the financial results for the first nine months of
2021, the outlook for 2021 is updated. The updated outlook is
reflecting higher than expected Ozempic® market share gains, GLP-1
market growth and obesity care sales, mainly in the US.
Outlook 2021
(CER) |
Expectations 29
October |
Expectations 4
August |
Sales growth |
12-15% |
10-13% |
Operating profit growth |
12-15% |
9-12% |
Novo Nordisk’s full disclosure of the financial results for the
first nine months of 2021 will be published on 3 November 2021.
The above expectations are based on assumptions including those
described on pages 16 and 17 of the Financial report for the period
1 January 2021 to 30 June 2021 (Company Announcement No 48 /
2021).
The forward-looking statements on page 21 of the Financial
report for the period 1 January 2021 to 30 June 2021 (Company
Announcement No 48 / 2021) also apply to this company
announcement.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo
Nordisk employs about 45,800 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media: |
|
|
Mette Kruse
Danielsen |
+45 3079 3883 |
mkd@novonordisk.com |
Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
David Heiberg
Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
Mark Joseph
Root |
+1 848 213
3219 |
mjhr@novonordisk.com |
Company announcement No 64 / 2021
- PR211029_Q3 guidance update
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024